查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870328

化療嗜中性白血球低下症市場：依產品類型、治療方法、給藥途徑、最終使用者、通路、治療環境、病患小組和劑量強度分類－2025-2032年全球預測

Chemotherapy Induced Neutropenia Market by Product Type, Therapy, Route Of Administration, End User, Distribution Channel, Treatment Setting, Patient Group, Dosage Strength - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，化療引起的嗜中性白血球低下症市場規模將達到 107.8 億美元，複合年成長率為 4.16%。

關鍵市場統計數據
基準年 2024 77.7億美元
預計年份：2025年 81億美元
預測年份 2032 107.8億美元
複合年成長率 (%) 4.16%

全面概述影響化療引起的嗜中性白血球低下症(CIN) 治療全過程的關鍵臨床挑戰、治療模式和相關人員優先事項。

本執行摘要探討了化療引起的嗜中性白血球低下症(CIN) 的臨床、商業性和營運方面，這些方面正在影響整個醫療保健系統相關人員的優先事項。它重點闡述了治療創新、交付模式和衛生經濟學之間不斷演變的相互作用，這些相互作用將影響患者、醫療保健提供者和製造商如何應對與細胞毒性治療方法相關的嗜中性白血球低下症風險。其目標是對驅動治療選擇、臨床轉變和政策應對的因素進行簡明扼要、全面闡述，並重點介紹相關人員可採取的戰術性措施。

臨床創新、治療地點轉移、供應鏈韌性和基於績效的報銷如何改變化療引起的嗜中性白血球低下症(CIN) 的格局

近年來，技術進步、法規演變和醫療服務模式的轉變顯著改變了化療引起的嗜中性白血球低下症（CIN）的現狀。臨床創新，例如長效粒細胞集落刺激因子（G-CSF）製劑和生物相似藥的引入，豐富了治療選擇，並引入了關於給藥頻率、依從性和治療部位適用性的新考慮。同時，精準癌症醫學正在改善化療方案和支持治療流程，鼓勵臨床醫生採用個人化的預防和治療方法，以反映患者的風險狀況和治療目標。

了解2025年美國關稅變化對治療化療引起的嗜嗜中性白血球低下症減少症藥物的生產、採購和臨床獲取動態的影響

2025年美國關稅的累積影響為化療引起的嗜中性白血球低下症（CIN）治療系統帶來了新的複雜性，影響了生產策略、採購選擇和價格談判。生物製藥原料和成品的關稅調整迫使製造商重新評估全球採購決策，加速區域產能擴張，並在可能的情況下透過關稅工程和重新分類尋求關稅減免。這些策略對前置作業時間、庫存管理政策和低溫運輸物流有著直接的營運影響，而這些對於維持G-CSF療法的持續供應至關重要。

透過深度細分分析，將產品屬性、治療目的、給藥途徑和分銷管道連結起來，從而製定可行的臨床和商業策略。

基於細分市場的洞察揭示了影響臨床實踐和商業策略的各種細微機會和限制因素，涵蓋了產品系列、治療目標和供應鏈管道。依產品類型分類，競爭格局既包括成熟的治療方法，例如非Filgrastim和Pegfilgrastim，也包括新型分子，例如依弗拉格司亭和長效聚乙二醇化製劑。所有這些產品在給藥頻率、給藥便利性和低溫運輸要求方面都各具特色。在治療方法中，預防性給藥和治療性給藥之間的區別清晰地體現了不同的應用促進因素：預防性給藥優先考慮可預測的給藥方案和依從性，而治療性給藥則強調嗜中性白血球的快速恢復和急性反應。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大長效培Pegfilgrastim生物相似藥的使用，以提高不同腫瘤患者群體預防性治療的可近性和成本效益
  • 將人工智慧驅動的風險分層工具整合到臨床實踐中，以製定嗜中性白血球低下症減少症預防和治療方案。
  • 在區域癌症治療中引入口服髓系造血因子，以提高患者的便利性和用藥依從性。
  • 越來越重視產生真實世界證據，以證明嗜中性白血球低下症症干預措施的成本效益和治療結果
  • 擴大遠端醫療嗜中性白血球低下症管理項目，以對農村患者群體進行遠端監測和早期療育
  • 新興的基於價值的報銷模式將嗜中性白血球低下症的治療結果與支付方的合約和定價策略聯繫起來。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章化療嗜中性白血球低下症市場（依產品類型分類）

  • 依夫拉帕格司亭
  • Filgrastim
  • Pegfilgrastim
  • Pegfilgrastim

第9章化療嗜中性白血球低下症市場（依治療方法）

  • 預防
  • 治療

第10章化療引起的嗜中性白血球低下症市場（依給藥途徑分類）

  • 靜脈注射
  • 皮下注射

第11章化療嗜中性白血球低下症市場（依最終用戶分類）

  • 診所
  • 居家照護
  • 醫院

第12章化療引起的嗜中性白血球低下症市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章化療嗜中性白血球低下症市場（依治療方案分類）

  • 住院病人
  • 門診

第14章化療嗜中性白血球低下症市場（依病患小組分類）

  • 成人
  • 老年人
  • 兒童

第15章 依劑量強度分類的化療引起的嗜中性白血球低下症症市場

  • 5 Mcg/Kg
  • 6 mg

第16章化療嗜中性白血球低下症市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章化療嗜中性白血球低下症市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章化療嗜中性白血球低下症市場（依國家分類）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 競爭情勢

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Amgen Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Pfizer Inc.
    • Viatris Inc.
    • Biocon Ltd.
    • Fresenius Kabi AG
    • Intas Pharmaceuticals Ltd.
    • Cipla Ltd.
    • Lupin Ltd.
Product Code: MRR-1A1A064BFFBE

The Chemotherapy Induced Neutropenia Market is projected to grow by USD 10.78 billion at a CAGR of 4.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.77 billion
Estimated Year [2025] USD 8.10 billion
Forecast Year [2032] USD 10.78 billion
CAGR (%) 4.16%

An integrated introduction to the clinical imperatives, delivery models, and stakeholder priorities shaping responses to chemotherapy induced neutropenia across care continua

This executive summary introduces the clinical, commercial, and operational dimensions of chemotherapy induced neutropenia (CIN) that are shaping stakeholder priorities across healthcare systems. The focus here is on the evolving interplay between therapeutic innovation, delivery models, and healthcare economics that determine how patients, providers, and manufacturers respond to neutropenia risk associated with cytotoxic regimens. The objective is to present a concise, integrated account of the forces driving treatment choice, site-of-care transitions, and policy responses, while highlighting the tactical levers available to stakeholders.

Clinicians and health system leaders are increasingly balancing acute risk mitigation against long-term outcomes by integrating granulocyte colony-stimulating factor (G-CSF) strategies into broader oncology care pathways. At the same time, manufacturers and distributors contend with changing supply chain expectations and evolving reimbursement frameworks. As a result, decision-makers must synthesize clinical evidence, operational feasibility, and payer dynamics to optimize patient safety and resource utilization. This introduction sets the stage for a deeper examination of transformative shifts, regulatory and trade headwinds, segmentation-driven nuances, regional contrasts, competitive behaviors, and concrete recommendations for industry leaders.

How clinical innovation, site-of-care migration, supply chain resilience, and outcomes-driven reimbursement are collectively transforming the chemotherapy induced neutropenia landscape

Significant transformative shifts have reshaped the CIN landscape over recent years, driven by technological advances, regulatory evolution, and changing care delivery paradigms. Clinical innovation in long-acting G-CSF formulations and biosimilar entrants has diversified therapeutic options and introduced new considerations around dosing frequency, adherence, and site-of-care appropriateness. Concurrently, precision oncology has refined chemotherapy regimens and supportive care algorithms, prompting clinicians to adopt individualized prophylaxis and treatment approaches that reflect patient risk profiles and treatment intent.

Operationally, the migration of care from inpatient settings to outpatient clinics and home-based administration has accelerated, propelled by patient preference, cost considerations, and remote monitoring capabilities. Telehealth and digital patient support tools now facilitate symptom tracking and early intervention, reducing unnecessary hospital visits and enabling timely dose administration. From a regulatory and commercial perspective, heightened scrutiny on biologics manufacturing quality, cold chain integrity, and cross-border supply chain resilience has led organizations to invest in redundancy and nearshoring strategies to mitigate disruptions.

Payer and provider behaviors are also transforming as value-based contracting, real-world evidence generation, and outcomes-based reimbursement models gain traction. These mechanisms encourage manufacturers to demonstrate not only clinical efficacy but also measurable reductions in febrile neutropenia incidence, hospitalizations, and total cost of care. Taken together, these shifts are producing a more complex but opportunity-rich environment in which stakeholders who align clinical innovation with patient-centric delivery and robust evidence packages will secure competitive advantage.

Understanding how United States tariff changes in 2025 have reshaped manufacturing, procurement, and clinical access dynamics affecting chemotherapy induced neutropenia therapies

The cumulative impact of United States tariffs implemented in 2025 has introduced a new layer of complexity to the CIN ecosystem, influencing manufacturing strategies, procurement choices, and pricing negotiations. Tariff adjustments on biologics inputs and finished products have prompted manufacturers to reassess global sourcing decisions, accelerate regional manufacturing capacity builds, and seek tariff mitigation strategies through tariff engineering or reclassification where feasible. These strategies have direct operational implications for lead times, inventory policies, and cold chain logistics that are central to maintaining uninterrupted access to G-CSF therapies.

For health systems and payers, the tariff environment has elevated the importance of strategic procurement and formulary management. Hospitals and large clinic networks have responded by reassessing supplier diversification, renegotiating contracting terms, and intensifying scrutiny of total cost of care rather than unit price alone. Meanwhile, manufacturers and distributors have prioritized transparent communication on cost drivers and engaged in collaborative value-sharing conversations with payers to limit patient access disruptions.

Clinicians and pharmacy leaders are navigating the potential downstream effects on therapeutic choice and site-of-care decision-making. In some instances, incremental supply chain costs have encouraged the adoption of alternative administration settings, such as outpatient or home care, to offset facility-related expenses. Throughout this period of adjustment, stakeholders have emphasized robust scenario planning, supply chain visibility, and proactive regulatory engagement to stabilize access and preserve continuity of care for patients at risk of neutropenia.

Deep segmentation insights that connect product characteristics, therapeutic intent, administration routes, and distribution channels to actionable clinical and commercial strategies

Segmentation-driven insights reveal nuanced opportunities and constraints across product portfolios, therapeutic intent, and delivery channels that influence clinical practice and commercial strategy. Based on product type, the competitive environment spans long-acting pegylated agents and emerging molecules such as eflapegrastim alongside established therapies like filgrastim and lipegfilgrastim, which collectively present differentiated profiles in dosing frequency, administration convenience, and cold chain requirements. Based on therapy, the dichotomy between prophylaxis and treatment creates distinct adoption drivers; prophylaxis prioritizes predictable scheduling and adherence, whereas treatment emphasizes rapid neutrophil recovery and acute response.

Based on route of administration, the choice between intravenous injection and subcutaneous injection affects site-of-care selection, nursing workload, and patient preference, with subcutaneous options facilitating outpatient and home-based models. Based on end user, clinics, home care programs, and hospitals demonstrate divergent operational capabilities and reimbursement models, necessitating tailored service offerings and patient support initiatives. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each entail different procurement cycles, dispensing protocols, and patient touchpoints that shape adherence and follow-up.

Based on treatment setting, inpatient and outpatient contexts influence timing of prophylaxis, monitoring intensity, and escalation protocols. Based on patient group, adult, geriatric, and pediatric populations require differentiated dosing approaches, safety monitoring, and caregiver education to manage neutropenia risk effectively. Finally, based on dosage strength, standard regimens such as weight-based 5 mcg/kg dosing and fixed 6 mg options create alternate pathways for administration scheduling, patient convenience, and inventory management. Synthesizing these segmentation lenses enables stakeholders to prioritize interventions that align clinical characteristics with operational feasibility and payer expectations.

How regional variations across the Americas, Europe Middle East & Africa, and Asia-Pacific shape access, adoption, and supply chain strategies for neutropenia management

Regional dynamics exert a strong influence on access patterns, regulatory expectations, and operational priorities across the CIN landscape. In the Americas, clinical practice reflects rapid adoption of long-acting G-CSF formulations and a strong emphasis on outpatient and home-based care models, supported by integrated payer-provider systems that incentivize reductions in hospital utilization. Supply chain resilience and domestic manufacturing considerations have become focal points for stakeholders seeking to stabilize access and respond to tariff-driven cost pressures.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks, reimbursement pathways, and healthcare infrastructure creates a mosaic of adoption rates and procurement behaviors. Some markets favor biosimilar adoption and cost-containment measures, while others emphasize clinical continuity and brand-name therapeutics. The region's diverse treatment settings, from advanced tertiary centers to resource-constrained facilities, necessitate adaptable product portfolios and flexible distribution strategies.

In Asia-Pacific, rapid expansion of oncology services, growing biologics manufacturing capacity, and evolving regulatory harmonization are accelerating availability of both originator and biosimilar G-CSF therapies. Manufacturers that invest in regional manufacturing and local partnership models often realize reduced lead times and enhanced market responsiveness. Across all regions, harmonized pharmacovigilance, cold chain infrastructure, and payer engagement remain essential components for sustained access and scalable adoption of neutropenia management strategies.

Corporate strategies and competitive imperatives centered on innovation, manufacturing resilience, value-based contracting, and integrated patient support models

Competitive behavior among key companies in the CIN space reflects a dual focus on product innovation and commercial execution. Leading biologics developers and their partners are investing in next-generation formulations, real-world evidence programs, and patient support services that reduce barriers to adherence and facilitate outpatient administration. These firms are also expanding manufacturing footprints and implementing quality-by-design approaches to enhance batch reliability and regulatory compliance, thereby strengthening supply chain assurance for temperature-sensitive therapies.

In parallel, several incumbents and new entrants are pursuing differentiated value propositions that combine clinical convenience, cost-effectiveness, and bundled service offerings. Strategic alliances between manufacturers, specialty pharmacies, and home health providers are emerging to streamline patient onboarding, cold chain handling, and follow-up care. Companies that can demonstrate measurable reductions in febrile neutropenia events and hospital admissions through robust data packages and pilot programs are more likely to achieve favorable formulary positions and payer agreements.

Across the competitive set, successful companies emphasize agility in contracting, willingness to participate in outcomes-based arrangements, and investment in digital tools that support adherence and remote monitoring. These capabilities enable organizations to respond to tariff-driven cost pressures, shifting site-of-care preferences, and the increasing demand for patient-centric, value-driven solutions.

Actionable, operationally grounded recommendations for industry leaders to strengthen supply chains, enable home-based care, and secure payer-aligned value propositions

Industry leaders can convert insights into measurable advantage by implementing a set of pragmatic, actionable strategies that align clinical efficacy with operational and commercial objectives. First, invest in supply chain diversification and regional manufacturing to mitigate trade-related risks and to shorten lead times for temperature-sensitive biologics. Complement these investments with enhanced cold chain visibility and contingency inventory policies to preserve continuity of care during disruptions.

Second, prioritize product and service bundles that enable safe home administration and outpatient management, including nurse-led training, digital monitoring platforms, and specialty pharmacy coordination. These approaches reduce facility burden and improve patient experience while supporting adherence to prophylactic regimens. Third, develop robust real-world evidence generation plans and engage payers early to translate clinical impact into reimbursement value, leveraging pilot programs that quantify reductions in febrile neutropenia and associated hospital utilization.

Fourth, adopt flexible contracting and innovative pricing models, such as outcomes-based agreements or risk-sharing arrangements, to address payer concerns and to demonstrate alignment with broader healthcare efficiency goals. Fifth, tailor commercialization strategies to segmentation nuances by aligning product attributes-such as fixed-dose options or weight-based dosing-with the operational capabilities of clinics, hospitals, and home care providers. By executing these recommendations with disciplined change management and cross-functional coordination, industry leaders will position themselves to capture clinical trust and payer support while preserving patient access.

A rigorous, mixed-methods research methodology combining stakeholder interviews, literature synthesis, and supply chain analysis to produce validated and actionable insights

The research approach underpinning this executive summary integrates qualitative and quantitative methods designed to ensure reliability, transparency, and practical relevance. Primary research included structured interviews with clinical leaders in oncology and supportive care, pharmacy directors across hospital and outpatient settings, specialty pharmacy operators, and payer representatives to capture contemporary practice patterns and reimbursement considerations. These stakeholder insights were supplemented by protocol reviews and analyses of published clinical guidelines to contextualize therapeutic decision-making and prophylaxis criteria.

Secondary research leveraged peer-reviewed literature, regulatory guidance documents, and clinical trial registries to validate safety and efficacy considerations for G-CSF therapies and to trace recent regulatory developments. Supply chain and policy analyses incorporated publicly available trade policy documentation and industry advisories to understand the operational implications of tariff changes and manufacturing shifts. Data triangulation methods were applied throughout to reconcile differing perspectives and to identify consistent trends.

Quality assurance measures included cross-validation of interview findings, methodological transparency in data sourcing, and iterative expert review cycles to refine conclusions. Ethical considerations and data privacy were maintained by anonymizing primary interview inputs and by adhering to accepted standards for handling proprietary information. Together, these methods produced a synthesis that balances clinical nuance with operational and commercial intelligence for decision-makers.

A conclusive synthesis emphasizing the necessity of coordinated clinical, commercial, and operational strategies to secure patient access and long-term value in neutropenia management

In conclusion, the management of chemotherapy induced neutropenia is at an inflection point where clinical innovation, shifting care delivery models, supply chain dynamics, and evolving reimbursement expectations converge. Stakeholders that proactively integrate long-acting therapeutic options, enable safe outpatient and home-based administration, and invest in resilient manufacturing and distribution will be best positioned to safeguard patient access and demonstrate value to payers. Tariff-driven pressures and regional variability require strategic adaptation, yet they also present opportunities for competitive differentiation through localized manufacturing and service innovation.

Decision-makers should approach CIN strategy holistically, aligning clinical protocols, commercial models, and operational capabilities to deliver measurable improvements in patient outcomes and health system efficiency. By adopting targeted segmentation strategies, engaging payers with robust evidence packages, and prioritizing patient-centric delivery, organizations can navigate current headwinds and capture long-term opportunities created by the transition to value-focused oncology care. This synthesis underscores the imperative for coordinated action across clinical, commercial, and operational domains to achieve sustainable improvement in neutropenia management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of long-acting pegfilgrastim biosimilars improving prophylaxis access and affordability for diverse oncology populations
  • 5.2. Integration of AI-driven risk stratification tools for personalized neutropenia prevention and treatment planning in clinical settings
  • 5.3. Adoption of oral myeloid growth factors to enhance patient convenience and adherence in community oncology practices
  • 5.4. Rising emphasis on real-world evidence generation to demonstrate cost-effectiveness and outcomes of neutropenia interventions
  • 5.5. Growth of telehealth-supported neutropenia management programs for remote monitoring and early intervention in rural patient cohorts
  • 5.6. Emergence of value-based reimbursement models linking neutropenia treatment outcomes to payer contracting and pricing strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chemotherapy Induced Neutropenia Market, by Product Type

  • 8.1. Eflapegrastim
  • 8.2. Filgrastim
  • 8.3. Lipegfilgrastim
  • 8.4. Pegfilgrastim

9. Chemotherapy Induced Neutropenia Market, by Therapy

  • 9.1. Prophylaxis
  • 9.2. Treatment

10. Chemotherapy Induced Neutropenia Market, by Route Of Administration

  • 10.1. Intravenous Injection
  • 10.2. Subcutaneous Injection

11. Chemotherapy Induced Neutropenia Market, by End User

  • 11.1. Clinic
  • 11.2. Home Care
  • 11.3. Hospital

12. Chemotherapy Induced Neutropenia Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Chemotherapy Induced Neutropenia Market, by Treatment Setting

  • 13.1. Inpatient
  • 13.2. Outpatient

14. Chemotherapy Induced Neutropenia Market, by Patient Group

  • 14.1. Adult
  • 14.2. Geriatric
  • 14.3. Pediatric

15. Chemotherapy Induced Neutropenia Market, by Dosage Strength

  • 15.1. 5 Mcg/Kg
  • 15.2. 6 Mg

16. Chemotherapy Induced Neutropenia Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Chemotherapy Induced Neutropenia Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Chemotherapy Induced Neutropenia Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Amgen Inc.
    • 19.3.2. Teva Pharmaceutical Industries Ltd.
    • 19.3.3. Sandoz International GmbH
    • 19.3.4. Pfizer Inc.
    • 19.3.5. Viatris Inc.
    • 19.3.6. Biocon Ltd.
    • 19.3.7. Fresenius Kabi AG
    • 19.3.8. Intas Pharmaceuticals Ltd.
    • 19.3.9. Cipla Ltd.
    • 19.3.10. Lupin Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 5 MCG/KG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY 6 MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLIO